Stereotaxis, Inc. (NYSE:STXS) Q1 2023 Earnings Conference Call May 9, 2023 10:00 AM ET Company Participants David Fischel - CEO & Chairman Kimberly Peery - CFO & Secretary Conference Call Participants Joshua Jennings - TD Cowen Frank Takkinen - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Capital Group Neil Chatterji - B. Riley Securities Adam Maeder - Piper Sandler Operator Good morning. Thank you for joining us for Stereotaxis' First Quarter 2023 Earnings Conference Call. Certain statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Jurisdiction o ...

Financial Data and Key Metrics Changes - Revenue for the fourth quarter of 2022 totaled $7.3 million, down from $8.2 million in the prior year fourth quarter. Full year revenue was $28.1 million compared to $35 million in 2021 [45][47] - System revenue for the full year 2022 was $6.8 million, compared to $11.2 million in the prior year, impacted by hospital construction delays [45][47] - Recurring revenue for the full year was $21.3 million, down from $22.9 million, reflecting procedure volatility and service renewal timing [20][47] - Operating loss for the fourth quarter was $4.5 million, compared to approximately $3.4 million for the previous year [21][47] - Adjusted operating loss for the full year 2022 was $8.3 million, compared to $3.6 million in the prior year [47] Business Line Data and Key Metrics Changes - The company reported a system backlog of $14.8 million at the start of 2023, indicating potential revenue recognition from this backlog [18][43] - Gross margin for the fourth quarter and full year 2022 were approximately 59% and 66% of revenue, respectively [20][45] - System gross margins reflect significant allocations of fixed overhead expenses, with full year gross margins of 82% on recurring revenue and 15% for system revenue [20][47] Market Data and Key Metrics Changes - Approximately 40% of procedure volume comes from Europe, with significant interest in the upcoming MAGiC catheter launch [30][34] - The company expects to see a recovery in procedures in China as COVID restrictions ease, which should positively impact recurring revenue [65] Company Strategy and Development Direction - The company aims to transform endovascular surgery with robotics, addressing limitations of manual handheld catheters [8][9] - Key innovations include the MAGiC catheter, a smaller self-shielding robot, and a family of interventional guidewires and catheters, which are expected to drive growth [13][40] - The company is focused on building a robust sales team and improving its capital sales strategy to enhance market penetration [100] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth in 2023, driven by backlog revenue recognition and new system orders [18][23] - The company anticipates that the launch of new products will significantly accelerate both system and recurring revenue adoption in the coming years [23][88] - Management acknowledged the challenges posed by hospital construction delays and the need for improved customer urgency in the sales process [72][93] Other Important Information - The company moved into a new custom-built headquarters and manufacturing facility, which is expected to enhance operations and support future growth [42][44] - The company has approximately $30 million in cash and no debt, providing a strong balance sheet to support its strategic initiatives [44][49] Q&A Session Summary Question: What is the expected adoption of the MAGiC catheter in Europe? - Management noted strong excitement among physicians for the MAGiC catheter, with plans for a limited market release to ensure a smooth launch [26][53] Question: What are the expectations for system revenue growth in 2023? - Management expects system revenue to grow due to recognizing the majority of the backlog and increased orders compared to 2022 [71][78] Question: How does the company plan to address the sales cycle challenges? - Management highlighted the importance of building a robust capital sales team and improving customer engagement to drive urgency in the sales process [100][105]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Juris ...

Stereotaxis, Inc. (NYSE:STXS) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants David Fischel - CEO & Chairman Kimberly Peery - CFO & Secretary Conference Call Participants Adam Maeder - Piper Sandler Neil Chatterji - B. Riley Securities Frank Takkinen - Lake Street Capital Markets Alexander Nowak - Craig-Hallum Joshua Jennings - Cowen Javier Fonseca - Spartan Capital Operator Good morning. Thank you for joining us for Stereotaxis' Third Quarter 2022 Earnings Conference Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Jurisdicti ...

Stereotaxis, Inc. (NYSE:STXS) Q2 2022 Earnings Conference Call August 9, 2022 10:00 AM ET Company Representatives David Fischel - Chairman, Chief Executive Officer Kim Peery - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Adam Maeder - Piper Sandler Neil Chatterji - B. Riley Alex Nowak - Craig-Hallum Capital Group Frank Takkinen - Lake Street Capital Markets Nathan Weinstein - Aegis Capital Javier Fonseca - Spartan Capital Operator Good morning! Thank you for joining us for Ster ...

INVESTOR PRESENTATION 1Q 2022 FORWARD LOOKING STATEMENT 2 During the course of this presentation, the Company may make projections and other forward-looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth opportunities and other statements that refer to Stereotaxis' plans, prospects, expectations, strategies, intentions and beliefs. These statements are subject to many risks and uncerta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36159 STEREOTAXIS, INC. (Exact name of the Registrant as Specified in its Charter) DELAWARE 94-3120386 (State or Other Jurisdict ...

Stereotaxis, Inc. (NYSE:STXS) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Market Adam Maeder - Piper Sandler Alex Nowak - Craig-Hallum Capital Group Jason Wittes - Loop Capital Javier Fonseca - Spartan Capital Operator Good morning. Thank you for joining us for Stereotaxis' First Quarter 2022 Earnings Conference Call. Certain statements dur ...